影像学无进展生存期与临床无进展生存期作为转移性激素敏感性前列腺癌男性总生存期潜在替代终点的研究
该研究基于9项随机试验的6390例转移性激素敏感性前列腺癌患者个体数据,验证影像学无进展生存期(rPFS)和临床无进展生存期(cPFS)是否为总生存期(OS)的有效替代终点。中位OS为4.3年,rPFS为2.4年,cPFS为2.3年;rPFS和cPFS的替代阈值效应分别为0.80和0.81。作者认为rPFS和cPFS是有前景的替代终点,STE≥0.80时可在以睾酮抑制为骨架治疗的III期试验中作为主要终点以加速试验进程。
要点
- 在mHSPC中,rPFS和cPFS均显示为有前景的OS替代终点。
- rPFS和cPFS的替代阈值效应分别为0.80和0.81。
- STE≥0.80使rPFS或cPFS可作为以睾酮抑制为骨架的III期mHSPC试验的主要替代终点。
核心结论
- rPFS和cPFS似乎均为有前景的OS替代终点;STE≥0.80使rPFS或cPFS可作为以睾酮抑制为骨架治疗的III期mHSPC试验中替代OS的主要终点,并加速试验进程。
研究设计与样本
- 研究获取9项合格随机试验的个体患者数据,这些试验比较不同雄激素剥夺治疗(ADT)策略或ADT联合多西他赛(对照组或研究组)治疗mHSPC。
- 采用两阶段荟萃分析验证模型,需满足患者水平和试验水平替代条件,并计算替代阈值效应(STE)。
- 汇总1994年至2012年随机分配的来自13个单位的6390例患者个体数据进行分层分析。
主要发现
- 中位OS为4.3年(95%CI 4.2至4.5),中位rPFS为2.4年(95%CI 2.3至2.5),中位cPFS为2.3年(95%CI 2.2至2.4)。
- rPFS的STE为0.80,cPFS的STE为0.81。
关键数值与推荐
- rPFS定义为从随机分组至影像学进展或任何原因死亡(以先发生者为准)的时间。
- cPFS定义为从随机分组至影像学进展、症状出现、开始新治疗或死亡(以先发生者为准)的时间。
- rPFS的STE为0.80,cPFS的STE为0.81。
临床怎么用
- 作者认为,在以睾酮抑制为骨架治疗的III期mHSPC试验中,STE≥0.80使rPFS或cPFS可作为替代OS的主要终点,并加速试验进程。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Despite major increases in the longevity of men with metastatic hormone-sensitive prostate cancer (mHSPC), most men still die of prostate cancer. Phase III trials assessing new therapies in mHSPC with overall survival (OS) as the primary end point will take approximately a decade to complete. We investigated whether radiographic progression-free survival (rPFS) and clinical PFS (cPFS) are valid surrogates for OS in men with mHSPC and could potentially be used to expedite future phase III clinical trials. METHODS: We obtained individual patient data (IPD) from 9 eligible randomized trials comparing treatment regimens (different androgen deprivation therapy [ADT] strategies or ADT plus docetaxel in the control or research arms) in mHSPC. rPFS was defined as the time from random assignment to radiographic progression or death from any cause whichever occurred first; cPFS was defined as the time from random assignment to the date of radiographic progression, symptoms, initiation of new treatment, or death, whichever occurred first. We implemented a two-stage meta-analytic validation model where conditions of patient-level and trial-level surrogacy had to be met. We then computed the surrogate threshold effect (STE). RESULTS: IPD from 6,390 patients randomly assigned from 1994 to 2012 from 13 units were pooled for a stratified analysis. The median OS, rPFS, and cPFS were 4.3 (95% CI, 4.2 to 4.5), 2.4 (95% CI, 2.3 to 2.5), and 2.3 years (95% CI, 2.2 to 2.4), respectively. The STEs were 0.80 and 0.81 for rPFS and cPFS end points, respectively. CONCLUSION: Both rPFS and cPFS appear to be promising surrogate end points for OS. The STE of 0.80 or higher makes it viable for either rPFS or cPFS to be used as the primary end point that is surrogate for OS in phase III mHSPC trials with testosterone suppression alone as the backbone therapy and would expedite trial conduct.
引用
- Halabi S, Roy A, Rydzewska L, et al. Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2024. PMID: 38181323. doi:10.1200/JCO.23.01535
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。